SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Chow E,Harris K,Fan G, et al. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol. 2007; 25: 14231436.
  • 2
    Wu JS,Wong RK,Lloyd NS, et al. Radiotherapy fractionation for the palliation of uncomplicated painful bone metastases—an evidence-based practice guideline. BMC Cancer. 2004; 4: 17.
  • 3
    Wu JS,Wong R,Johnston M, et al. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys. 2003; 55: 594605.
  • 4
    van der Linden YM,Steenland E,van Houwelingen HC, et al. Patients with a favourable prognosis are equally palliated with single and multiple fraction radiotherapy: results on survival in the Dutch Bone Metastasis Study. Radiother Oncol. 2006; 78: 245253.
  • 5
    Roos DE,Turner SL,O'Brien PC, et al. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 9605) Radiother Oncol. 2005; 75: 5463.
  • 6
    Sze WM,Shelley M,Held I,Mason M. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy—a systematic review of the randomised trials. Cochrane Database Syst Rev. 2004;(2): CD004721.
  • 7
    Roos DE,O'Brien PC,Smith JG, et al. A role for radiotherapy in neuropathic bone pain: preliminary response rates from a prospective trial (Trans-Tasman Radiation Oncology Group, TROG 9605) Int J Radiat Oncol Biol Phys. 2000; 46: 975981.
  • 8
    [No authors listed] Eight Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Bone Pain Trial Working Party. Radiother Oncol. 1999; 52: 111121.
  • 9
    Rades D,Fehlauer F,Schulte R, et al. Prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression. J Clin Oncol. 2006; 24: 33883393.
  • 10
    Rades D,Stalpers LJ,Veninga T, et al. Evaluation of 5 radiation schedules and prognostic factors for metastatic spinal cord compression. J Clin Oncol. 2005; 23: 33663375.
  • 11
    Pollicino CA,Turner SL,Roos DE, et al. Costing the components of pain management: analysis of Trans-Tasman Radiation Oncology Group trial (TROG 96.05): 1 versus 5 fractions for neuropathic bone pain. Radiother Oncol. 2005; 76: 264269.
  • 12
    van den Hout WB,van der Linden YM,Steenland E, et al. Single- versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. J Natl Cancer Inst. 2003; 95: 222229.
  • 13
    Katagiri H,Takahashi M,Wakai K, et al. Prognostic factors and a scoring system for patients with skeletal metastasis. J Bone Joint Surg Br. 2005; 87: 698703.
  • 14
    van der Linden YM,Dijkstra SP,Vonk EJ, et al. Prediction of survival in patients with metastases in the spinal column: results based on a randomized trial of radiotherapy. Cancer. 2005; 103: 320328.
  • 15
    Rades D,Karstens JH,Hoskin PJ, et al. Escalation of radiation dose beyond 30 Gy in 10 fractions for metastatic spinal cord compression. Int J Radiat Oncol Biol Phys. 2007; 67: 525531.
  • 16
    Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys. 1982; 8: 19811997.
  • 17
    Joiner MC,Van der Kogel AJ. The linear-quadratic approach to fractionation and calculation of isoeffect relationships. In: SteelGG, ed. Basic Clinical Radiobiology. New York, NY, Oxford University Press; 1997: 106112.
  • 18
    Gatzemeier U,Pluzanska A,Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007; 25: 15451552.
  • 19
    Herold M,Haas A,Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology study. J Clin Oncol. 2007; 25: 19861992.
  • 20
    Chatal JF,Campion L,Kraeber-Bodere F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol. 2006; 24: 17051711.
  • 21
    Mouridsen H,Gershanovich M,Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003; 21: 21012109.
  • 22
    Noda K,Nishiwaki Y,Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002; 346: 8591.
  • 23
    Berlin JD,Catalano P,Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002; 20: 32703275.
  • 24
    Boccardo F,Rubagotti A,Barichello M, et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol. 1999; 17: 20272038.
  • 25
    Kaplan EL,Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 26
    Harrington KD. Metastatic disease of the spine. J Bone Joint Surg Am. 1986; 68: 11101115.
  • 27
    Rades D,Veninga T,Stalpers LJ, et al. Outcome after radiotherapy alone for metastatic spinal cord compression in patients with oligometastases. J Clin Oncol. 2007; 25: 5056.
  • 28
    Rades D,Hoskin PJ,Karstens JH, et al. Radiotherapy of metastatic spinal cord compression in very elderly patients. Int J Radiat Oncol Biol Phys. 2007; 67: 256263.
  • 29
    Rades D,Fehlauer F,Veninga T, et al. Functional outcome and survival after radiotherapy of metastatic spinal cord compression in patients with cancer of unknown primary: functional outcome and survival after radiotherapy of metastatic spinal cord compression in patients with cancer of unknown primary. Int J Radiat Oncol Biol Phys. 2007; 67: 532537.
  • 30
    Rades D,Veninga T,Stalpers LJ, et al. Prognostic factors predicting functional outcomes, recurrence-free survival, and overall survival after radiotherapy for metastatic spinal cord compression in breast cancer patients. Int J Radiat Oncol Biol Phys. 2006; 64: 182188.
  • 31
    Rades D,Stalpers LJ,Veninga T, et al. Evaluation of functional outcome and local control after radiotherapy for metastatic spinal cord compression in patients with prostate cancer. J Urol. 2006; 175: 552556.
  • 32
    Rades D,Dunst J,Schild SE. The first score predicting overall survival in patients with metastatic spinal cord compression. Cancer. 2008; 112: 157161.